Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ALDX with free AI briefings, catalyst countdowns, and dilution alerts.

ALDX · Aldeyra Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$41M Cash on Hand
28.2mo Cash Runway
Follow ALDX by email Get an email when ALDX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ALDX, unsubscribe in one click. Privacy

📣 What ALDX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Reproxalap Ophthalmic Solution (0.1%) Allergic Conjunctivitis Phase 3 · NCT05234554 Completed
Reproxalap Ophthalmic Solution (0.25%) QID Dry Eye Phase 3 · NCT03879863 Completed
Reproxalap Ophthalmic Solution (0.25% Novel… Dry Eye Phase 3 · NCT03879863 Completed
Monthly ADX-2191 injection Primary Vitreoretinal Lymphoma Phase 3 · NCT07402876 Recruiting
ICM ADX-2191 injection Primary Vitreoretinal Lymphoma Phase 3 · NCT07402876 Recruiting
ADX-2191 Proliferative Vitreoretinopathy Phase 3 · NCT04136366 Completed
Reproxalap Non-infectious Anterior Uveitis Phase 3 · NCT03131154 Completed
ADX-102 1% Topical Dermal Cream (reproxalap) Sjogren-Larsson Syndrome Phase 3 · NCT03445650 Completed
Active topical NS2 1% dermatologic cream Sjögren-Larsson Syndrome Phase 2 · NCT02402309 Completed
NS2 Ophthalmic Drops (0.5%) Allergic Conjunctivitis Phase 2 · NCT02578914 Completed
NS2 Non-infectious Anterior Uveitis Phase 2 · NCT02406209 Completed
ADX-629 Atopic Dermatitis Phase 2 · NCT05717920 Completed
ADX-102 Ophthalmic Solution (0.1%) Dry Eye Syndromes Phase 2 · NCT03162783 Completed
ADX-102 Ophthalmic Lipid Solution (0.5%) Dry Eye Syndromes Phase 2 · NCT03162783 Completed
ADX-102 Ophthalmic Drops (0.1%) Conjunctivitis, Allergic Phase 2 · NCT03012165 Completed

Also used in these trials (approved or third-party drugs, not ALDX's own candidates): Lifitegrast, Prednisolone Acetate.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ALDX holds $41M in cash and short-term investments (as of Sep 30, 2026) and burns about $4.4M/quarter from operations, an estimated runway of 28.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 10 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ALDX files for a raise →

👥 Who Owns ALDX

Insiders 13.9% Institutions (127 holders) 55.5% Public and other holders 30.6%
HolderTypeShares% of sharesAs of
PERCEPTIVE ADVISORS LLC
10% owner
Insider 5,875,851 9.74% 2025-04-03
Barclays PLC Institution (13G, 5%+) 3,310,587 5.49% 2026-09-30
Todd C Brady
President and CEO, Director · +3.32M options
Insider 1,721,298 2.85% 2026-06-03
Richard Douglas
Director · +5,227 options
Insider 395,000 0.65% 2026-11-11
Stephen Machatha
Chief Development Officer · +202,427 options
Insider 221,799 0.37% 2025-08-11
Bruce Greenberg
Interim Chief Financial Officer · +252,280 options
Insider 126,382 0.21% 2024-08-12
Michael Alfieri
Principal Financial Officer
Insider 17,500 0.03% 2026-11-11
Darlene M Deptula-hicks
Director · +9,756 options
Insider 7,500 0.01% 2026-11-12
Nancy Miller-Rich
Director · +7,467 options
Insider 922 0.00% 2021-05-03

Share count 60,356,541 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-03-17 reproxalap NDA -19.4% -70.7% -47.3%
2026-03-16 Reproxalap NDA -22.5% +2.6% -56.1%
2025-12-16 Reproxalap NDA -20.5% +33.1% +38.9%

Browse all historical PDUFA outcomes →

Get the full ALDX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ALDX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.